Emerald Bioscience to Present at the KCSA Cannabis Investor Conference
05 janv. 2021 08h30 HE
|
Emerald Bioscience, Inc.
San Diego, Calif, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald” or the “Company”), a biopharmaceutical company focused on developing differentiated, proprietary...
Emerald Bioscience Reports that Superior Reduction of Intraocular Pressure of its Unique Nanoemulsion Formulation of THCVHS is Published in Peer-Reviewed Journal
16 déc. 2020 08h30 HE
|
Emerald Bioscience, Inc.
Drug Delivery and Translational Research article highlights significantly better drug load and duration of activity of prodrug of THC compared to leading commercial drugs for treating glaucoma San...
Emerald Bioscience to Present at the Benzinga Global Small Cap Virtual Conference
07 déc. 2020 08h45 HE
|
Emerald Bioscience, Inc.
San Diego, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald” or the “Company”), a preclinical-stage biopharmaceutical company focused on developing...
Emerald Bioscience Provides Corporate Update
30 sept. 2020 08h30 HE
|
Emerald Bioscience, Inc.
Renewed team and capital focused on advancing lead compound for glaucoma into human studies Ongoing development of lead compound, THCVHS, includes near-term preclinical assessments of neuroprotection...
Emerald Bioscience to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
03 sept. 2020 11h39 HE
|
Emerald Bioscience, Inc.
San Diego, CA, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI a preclinical-stage biopharmaceutical company focused on the development of proprietary first-in-class...
Emerald Bioscience Appoints Biotech Veteran Dr. Margaret Dalesandro to Board of Directors
13 août 2020 08h30 HE
|
Emerald Bioscience, Inc.
San Diego, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald” or the “Company”), a preclinical-stage biopharmaceutical company focused on the development of...
Emerald Bioscience Appoints Biotech Executive Punit Dhillon as CEO
10 août 2020 08h30 HE
|
Emerald Bioscience, Inc.
Renewed team and capital focused on advancing lead compound for glaucoma into clinical development San Diego, Calif, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI)...
Emerald Bioscience Raises approximately $7.0 Million in Upsized Registered Offering
04 août 2020 18h32 HE
|
Emerald Bioscience, Inc.
Long Beach, CA, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald”), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to address...
Emerald Bioscience Announces Pricing of $7.0 Million Upsized Registered Offering
31 juil. 2020 09h20 HE
|
Emerald Bioscience, Inc.
Long Beach, CA, July 31, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald”), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to address...
Emerald Bioscience Announces Presentation of Cannabidiol-Valine-Hemisuccinate Ocular Data at Virtual ARVO® Meeting
09 juin 2020 09h37 HE
|
Emerald Bioscience, Inc.
Bio-engineered analog of CBD (CBDVHS) exhibited highly significant potency when compared to CBD in lowering biomarkers associated with inflammation and fibrosis in a validated human tissue model of...